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Background: Objective of this study is to show the potential use of natural gums in the development of drug
delivery systems. Therefore in this work gastro retentive tablet formulations of ziprasidone HCl were developed
using simplex lattice design considering concentration of okra gum, locust bean gum and HPMC K4M as
independent variables. A response surface plot and multiple regression equations were used to evaluate the effect
of independent variables on hardness, flag time, floating time and drug release for 1 h, 2 h, and 8 h and for 24 h. A
checkpoint batch was also prepared by considering the constraints and desirability of optimized formulation to
improve its in vitro performance. Significance of result was analyzed using ANOVA and p < 0.05 was considered
statistically significant.
Results: Formulation chiefly contains locust bean gum found to be favorable for hardness and floatability but
combined effect of three variables was responsible for the sustained release of drug. The in vitro drug release data
of check point batch (F8) was found to be sustained well compared to the most satisfactory formulation (F7) of 7
runs. The ‘n’ value was found to be between 0.5 and 1 suggesting that release of drug follows anomalous (non-
fickian) diffusion mechanism indicating both diffusion and erosion mechanism from these natural gums. Predicted
results were almost similar to the observed experimental values indicating the accuracy of the design. In vivo
floatability test indicated non adherence to the gastric mucosa and tablets remain buoyant for more than 24 h.
Conclusions: Study showed these eco-friendly natural gums can be considered as promising SR polymers.
Keywords: Okra gum, Locust bean gum, Ziprasidone HCl, Gastro retentive tablet, Simplex lattice design, In vivo
floatabilityIntroduction
The use of naturally occurring hydrophilic biocompat-
ible polymeric materials has been focused in recent re-
search activity in the design of oral controlled release
dosage forms [1]. Natural gums are among the most
popular hydrophilic polymers because of their cost-
effectiveness and regulatory acceptance [2,3]. The use of
naturally occurring plant-based pharmaceutical excipi-
ents has become very important in the development of
controlled release dosage forms, because of their ability
to produce a wide range of material based on their prop-
erties and molecular weight [4]. Plant based materials* Correspondence: sbsateesh@gmail.com
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reproduction in any medium, provided the orcan be modified to meet the requirements of drug deliv-
ery systems and thus can compete with the synthetic
excipients available in the market [5].
Okra gum and locust bean gum are water soluble
thickening agents which have not been much studied
for their pharmaceutical applications [6]. Okra gum,
obtained from the fruits of Hibiscus esculentus L.
(Moench), Malvaceae, is a polysaccharide consisting of
D-galactose, L-rhamnose and L-galacturonic acid [7].
Locust bean gum (LBG) is a neutral plant galactoman-
nan extracted from the seed (kernels) of the carob tree
Ceratonia siliqua L. fabaceae [8]. The okra gum and
LBG shows a synergistic gelation in acidic pH [9,10] and
in combination with HPMC K4M forms an original gel-
ation which has an excellent buoyancy and useful for
oral gastro retentive formulations.This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 Equilateral triangle representing simplex lattice
design for 3 components (A, B and C).
Table 1 Formulations of ziprasidone HCl according to
simplex lattice design
Ingredients Formulation code*
F1 F2 F3 F4 F5 F6 F7 F8
Ziprasidone HCl 20 20 20 20 20 20 20 20
HPMC K4M 33.3 100 - - 16.7 16.7 66.7 74.6
Okra gum 33.3 - - 100 16.7 66.7 16.7 15.3
Locust bean gum 33.3 - 100 - 66.7 16.7 16.7 12.4
Sodium bicarbonate 40 40 40 40 40 40 40 40
Tartaric acid 10 10 10 10 10 10 10 10
Poly vinyl pyrrolidone 15 15 15 15 15 15 15 15
Magnesium stearate 1 1 1 1 1 1 1 1
Talc 1 1 1 1 1 1 1 1
Lactose Q.S 200 200 200 200 200 200 200 200
*All values are in mg.
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treatment of schizophrenia [11]. The systemic bioavail-
ability of ziprasidone administered intramuscularly is
100%, or 60%, administered orally with food. Drug
reaches peak plasma concentration in 6 to 8 h after oral
administration with an elimination half life of 7 h. This
drug is more soluble in acidic pH and its solubility
decreases with increasing pH owing to its pKa (~6) value
[12]. The beneficial delivery system would be gastrore-
tentive drug delivery systems which remain in the gastric
region for several hours and significantly prolong the
gastric residence time of drugs [13]. Hence, the goal has
been set to evaluate the potential of Okra gum and LBG
in combination with HPMC K4 for gastro retentive drug
delivery system of ziprasidone HCl using simplex lattice
design (SLD).
Materials and methods
Ziprasidone HCl (Sanofi Aventis Pharma, Ltd, India)
was received as a gift sample. HPMC K4M, okra gum
(okra seeds, market), locust bean gum (Sigma Aldrich,
Germany), and polyvinyl pyrollidone (Sisco research la-
boratories Pvt. Ltd) were purchased. All other chemicals
used in the study were of analytical grade. Stat-ease
Design-ExpertW software was used to design the
formulation.
Okra gum (pod mucilage)
The fresh A. esculentus fruits were collected and washed
with water. The fruits were crushed and soaked in water
for 5–6 h, boiled for 30 min and left to stand for 1 h to
allow complete release of the mucilage. The mucilage
was separated using a multi layer muslin cloth and was
precipitated by adding acetone (three times the volume
of filtrate). The precipitate obtained was collected, dried
in an oven at 40°C, and passed through a sieve #80 to
obtain discrete powder [14].
Simplex lattice design
A simplex lattice design was adopted to optimize the
formulation variables of gastro retentive drug delivery
system of ziprasidone HCl [15]. The simplex lattice de-
sign for a 3-component system is represented by an
equilateral triangle in 2-dimensional space (Figure 1). In
this design, 3 factors were evaluated by changing their
concentrations simultaneously and keeping their total
concentration constant. Seven batches (F1-F7) of tablet
formulations were prepared, one at each vertex (A, B,
C), one at the halfway point between vertices (AB, BC,
AC), and one at the center point (ABC). Each vertex
represents a formulation containing the maximum
amount of 1 component, with the other 2 components
at a minimum level. The halfway point between the 2
vertices represents a formulation containing the averageof the minimum and maximum amounts of the 2 ingre-
dients. The center point represents a formulation con-
taining one third of each ingredient.
Concentrations of HPMC K4M (A), okra gum (B) and
LBG (C) were selected as independent variables. Hard-
ness (kg/cm2), floating lag time (flag time, sec), drug re-
lease for 1 h (%), drug release for 2 h (%), drug release for
8h (%) and drug release for 24 h (%) were taken as re-
sponse values (Dependent variables). The response values
obtained were analyzed using multiple regression analysis
to find out their relationship with the factors used.Formulation of gastroretentive matrix tablets
Weighed quantity of drug, polymers, effervescent combin-
ation and diluent (Table 1) were passed through sieve #80,
mixed and triturated in a mortar for a period of 10min to
obtain uniform mixture. Powder was lubricated with mag-
nesium stearate and talcum powder for 3min. Lubricated
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Minipress RSB-1 tablet punching machine using 8 mm
concave punches. The dimensional specifications were
measured using thickness gauge (Okimoto); weight vari-
ation test was conducted as per pharmacopoeia of India
specifications. Hardness of the tablet was measured
using Pfizer type hardness tester.
Drug content estimation
Standard calibration curve of ziprasidone HCl was con-
structed using UV-Visible spectrophotometer (Shimadzu-
1700, Kyoto, Japan). Drug solution was prepared in
methanol at the concentration range of 10 μg/mL to
50 μg/mL, sonicated, filtered using 0.45 μ (Millipore)
membrane filter. The drug content of standard drug solu-
tion and tablet formulation was measured at 318 nm
against methanol as a blank solution [16]. This method
was found to have good repeatability, reproducibility and
relative standard deviation (RSD) was not more than 2%.
The working curve equation for ziprasidone HCl was
y=0.011x with correlation coefficient value, r2 = 0.999.
In vitro floatability
An in vitro floatability [17] of the formulation was deter-
mined by placing weighed tablet matrices in the USP
dissolution testing apparatus II, in 900 ml of simulated
gastric fluid (0.1N HCl, 0.2% NaCl) enzyme free at
37±0.5°C, rotated at 75 rpm.
The time required for the tablet to rise to the surface
and float was determined as flag time. Floating time was
the time, during which the tablet floats (including flag
time) in simulated gastric fluid dissolution medium [18].
Swelling index
The extent of swelling was measured in terms of percent
weight gain by the tablet [19]. Each tablet formulation
was kept in a beaker containing 100 mL of simulated
gastric fluid; the tablet was withdrawn, blotted with tis-
sue paper and reweighed. Then for every 1 h, weights of
the tablets were noted and the process was continuous
till the end of 6 h. The percentage weight gain by the
tablet was calculated using the formula
SI ¼ Mt  Moð Þ=Mof g  100;
where, SI is swelling index, Mt is the weight of tablet at
time “t”, and Mo is the weight of tablet at time “t”=0.
Dissolution studies
The release rate of ziprasidone HCl from floating matrix
tablets were determined using USP XXIV dissolution ap-
paratus (TDT-08T, Electrolab) Type-II (paddle) method
for 24 h. Study was carried out using 900 ml of simu-
lated gastric fluid (0.1 N HCl, 0.2% NaCl) enzyme free,at 37± 0.5°C at 75 rpm. Aliquot volume of 5 ml was
withdrawn from the dissolution apparatus hourly for 24
h and the samples were replaced with fresh prewarmed
dissolution medium. The withdrawn samples were suit-
ably diluted with methanol, filtered and drug content
was determined using UV-spectrophotometer.
Kinetic modeling on drug release profile
The dissolution profile of most satisfactory formulation of
7 runs and a check point batch (F8) were evaluated using
mathematical models to describe the kinetics of the drug-
release. The kinetics of drug release was evaluated for
Higuchi, Korsmeyer-peppas, first order and zero order
models to check the phenomena controlling the drug
release from tablets [20,21]. The goodness of fit was evalu-
ated using the correlation coefficient values (r2).
Statistical analysis
The statistical assessment of simplex lattice design res-
ponses were performed using ANOVA and by applying
the Student-t test. Model terms are significant if the cal-
culated ‘t’ value is less than the critical value of ‘t’ (0.05).
In vivo floatability
The in vivo floatability of F8 formulation loaded with bar-
ium sulphate was investigated by radiographic images (X-
ray photographs) of rabbit’s stomach for specific period of
time. Healthy rabbit weighing approximately 2.3 Kg was
used to assess in vivo floating behaviour. The animal was
fasted for 12 h and X-ray photograph was taken to ensure
absence of radio opaque material in the stomach. The
rabbit were made to swallow barium sulphate loaded tab-
let formulation with 30 ml of water. During the experi-
ment rabbit were not allowed to eat but water was
provided. At predetermined time intervals the radiograph
of abdomen was taken to locate the formulation [22].
The preclinical study protocol was approved by Insti-
tutional Animal Ethical Committee, (Proposal No.
IAEC/NCP/56/10) Nargund College of Pharmacy (NCP),
Bangalore, Karnataka, India. Experiments were con-
ducted according to the guidelines of committee for the




The drug release characteristics were varied according
to the types and proportion of matrix forming polymers
in the formulation. HPMC K4M was selected as a hydro-
philic matrixing agent [23]. LBG and Okra gum were
considered as gelling agents they impart sufficient integ-
rity to the tablets and works as release modifiers. Okra
gum is insoluble in gastric pH but enormously swells
which helps in retarding the drug release. Sodium









for 1 h (%)
F1 6.52± 0.33 92.0± 5.19 4.86± 0.63
F2 5.04±0.55 27.0± 5.29 11.31± 0.47
F3 5.24± 0.45 32.66± 3.51 4.39± 0.39
F4 3.00± 0.37 137.0± 27.87 10.13± 0.60
F5 5.66± 0.42 88.66± 14.57 4.93± 0.82
F6 4.24± 0.38 136.0± 16.09 4.83± 0.80
F7 5.16±0.29 43.33± 13.79 5.61± 1.00
F8 5.68± 0.52 37.33± 4.16 8.70± 0.41
aAll values are mean of 3 readings ± SD.
Figure 2 Response surface plot showing the effect of
concentration of HPMC K4M, okra gum and LBG on hardness
(kg/cm2) and (b) floating lag time (sec).
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acid upon contact with dissolution medium. The gas
generated is trapped and protected within the gel
(formed by hydration of HPMC K4 M), thus decreasing
the density of the tablet [24]. As the density of the tablet
falls below 1 (density of water), the tablet becomes
buoyant.
Simplex lattice design
The general equation for the response based SLD for
three components system consisting terms for pure
component and mixtures of component [25].
R ¼ B0 þ b1 A þ b2 B þ b3 C ð1Þ
where, R is the response variable and A, B and C are the
proportions of formulation components. b0 is the arith-
metic mean response of the 7 runs and b1, b2 and b3 are
estimated coefficient for the factor A, B and C respect-
ively. The coefficients can be calculated from the
responses of ‘R’ using a multiple regression equation.
The fitted equations relating the hardness, flag time, and
drug release for 1h, drug release for 2 h, drug release for
8h and drug release for 24 h to the transformed factor
were used to draw conclusions after considering the
magnitude of coefficient and the mathematical sign it
carries (i.e., positive or negative).
Effect of independent variables on hardness
R1 Hardnessð Þ ¼ 5:44A þ 3:54B þ 5:90C
ð2Þ
Although the statistical results infers {‘F’ value of 3.04
and ‘p’ value of 0.1370 (< 0.05)} the linear model equa-
tion is not significant for hardness, the values of regres-
sion coefficient infers, the concentration of HPMC K4Mormulation
se Drug release
for 2 h (%)
Drug release
for 8 h (%)
Drug release
for 24 h (%)
9.29± 0.81 27.39± 0.63 80.50± 0.83
21.05± 0.23 89.39± 0.46 -
8.02± 0.40 25.69± 0.40 82.36± 0.39
14.79± 0.59 31.67± 0.45 85.45± 0.60
6.60± 0.40 30.55± 1.89 87.75± 1.03
6.56± 0.34 31.05± 0.44 82.26±0.41
8.52± 0.61 31.31± 0.61 95.98± 0.47
14.83± 0.63 47.53± 0.87 97.58± 0.63
Figure 3 Response surface plot showing the effect of concentration of HPMC K4M, okra gum and LBG on % drug release for (a) 1 h,
(b) 2 h, (c) 8 h and (d) 24 h respectively.
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ness (Figure 2a). Because HPMC K4M (A) and LBG
(C) has sufficient cohesiveness and fibrous integrity
makes them to undergo binding and contributed for








flag time 12739.02 2
1 h drug release 37.79 2
2 h drug release 117.80 2
8 h drug release 947.0 2
24 h drug release 432.98 2
*p < 0.05 indicate model terms are significant*.Effect of independent variables on flag time
R2 flag time
  ¼ 32:58A þ 54:92  B þ 52:51  C ð3Þ
The linear equation for flag time indicates that the fac-






















HPMC K4M Is in range 0 1 1 1 3
Okra gum Is in range 0 1 1 1 3
LBG Is in range 0 1 1 1 3
Floating lag time Minimize 27 137 1 1 3
8h release Minimize 25.69 59.39 1 1 3
24h release Maximize 80.5 100 1 1 3
Solutions
(Desirability 0.642)
A B C flag time (sec) 8h release 24 h release
0.946 - 0.054 33.66 51.26 98.45
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model terms for flag time being significant with ‘F’ value
of 16.63 and ‘p’ value of 0.0062 (< 0.05) on a linear
model. Floating lag time was found to increase at higher
level of okra gum and decreases as the level of HPMC
K4M increases. This is due to high swelling property of
the later. Hence, a higher proportion of HPMC K4M is
important in the formulation to decrease the flag time.
This is also evident from the results of swelling index
determination (221.95 to 257.15 (%) for F1 to F7 at the
end of 6 h). Swelling index increases with increase in
concentration of HPMC K4M signifying its importance
for decrease in flag time [27].Effect of independent variables on drug release
The magnitude of coefficients observed for 1, 2, 8 and
24 h release obtained from the results of multiple linear
regression analysis is expressed in equations 4, 5, 6 and
7 respectively. The release rate and percentage drugFigure 4 Comparative release profiles of ziprasidone HCl
gastroretentive formulations.release for the 7 batches (F1 to F7) showed a wide vari-
ation (i.e., 80 to 95%) as shown in Table 2. Formulation
F2 prepared using only HPMC K4M, exhausted before
8h and fails to sustain the drug release till 24 h. This
highest value of percentage release observed in initial
hours is due to low value of both the independent vari-
ables (B and C), thus weakening the gel strength.
Drug release for 1h and 2h
R3 Drug relese for 1 hð Þ
¼ 9:75A þ 7:52B þ 2:97C ð4Þ
R4 Drug release for 2 hð Þ
¼ 16:80A þ 10:47B þ 5:07C ð5Þ
The equations 4 and 5 infer that the ‘A’ has more fa-
vorable effect on increase in drug release and the factor
‘B’ and ‘C’ in retarding drug release for 1 and 2 h. Al-
though, the model terms are not significant {‘p’ value ofFigure 5 Comparative drug release profile of F7 and F8
formulation.
Table 5 Comparison of experimented and predicted
values of check point batch “F8”
Parameter Predicted values Experimented values
Hardness (kg/cm2) 5.46 5.68 ± 0.52
Floating lag time (sec) 33.66 37.33 ± 4.16
% Drug release at 8 h 51.26 47.53 ± 0.87
% Drug release at 24 h 98.45 97.58 ± 0.63
aAll values are mean of 3 readings ± SD.
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it is understood that the water solubility of HPMC helps
in increasing drug release and the water insolubility but
the swellability of LBG and okra gum is responsible for
it [28]. Optimum concentration of HPMC must be there
in the formulation for immediate release of drug at ini-
tial hours.
Drug release for 8h and 24h
Concentration of HPMC K4M has important role in en-
hancing the drug release for 8 and 24 h and reverse is
true with concentration of okra gum and LBG. As the
concentration of okra gum and LBG increases, it causes
an increase in viscosity of the swollen gel matrix, which
decreases the water diffusion in to the core layer. De-
crease in hydration of matrix contributes more hin-
drance for drug diffusion and consequently decrease in
release rate [29]. This can be further elucidated with the
help of response surface plot (Figure 3).
R5 Drug release for 8 hð Þ
¼ 52:87A þ 27:64B þ 22:86C ð6Þ
R6 Drug release for 24 hð Þ
¼ 99:53A þ 82:02B þ 79:55C ð7Þ
The model terms for R5 (8 h release) and R6 (24 h re-
lease) were found to be significant with an ‘F’ value of
8.20 and 14.19, and ‘p’ value of 0.0264 and 0.0087 (<
0.05) respectively. These results clearly indicate that the
percentage drug release is strongly dependent on all the
selected independent variables. This equation infers that
the judicious combination of HPMC K4M, okra gum
and LBG is necessary [30] to control and sustain the
drug release for 24 h. Table 3 shows the results of the
analysis of variance (ANOVA), which was performed to
identify insignificant factors.Table 6 Kinetic modeling of drug dissolution profiles
Formulation code Zero order First order
r2 k r2 k
F7 0.993 4.089 0.878 0.0
F8 0.934 4.107 0.936 0.0Based on this analysis, formulation F7 was arbitrarily
selected as an optimized batch which releases the drug
satisfactorily till the end of 24 h in spite of its high flag
time of 43.33 ± 13.79 sec. In order to overcome the
drawbacks of F7 formulation a checkpoint batch F8 pre-
pared by considering the constraints and desirability to
improve (Table 4) its in vitro performance. The experi-
mental results of formulation F8 for flag time, total float-
ing time and swelling index were found to be 37.33 ±
4.16sec, > 24 h and 204.0 ± 5.30% (up to 6 h) respect-
ively. The in vitro drug release data was found to be sus-
tained well compared to the most satisfactory formulation
(F7) of 7 runs (Figure 4 and Figure 5). Predicted results
were almost similar to the observed experimental values
indicates the accuracy of the design (Table 5). All formula-
tions were found to be buoyant for more than 24 h.
Kinetic modeling on drug release profile
The release profile and kinetics of drug release are im-
portant because they correlate the in vitro and in vivo
drug responses by comparing results of pharmacokinet-
ics and dissolution profile patterns [31]. Hence, the cu-
mulative drug release results of F7 and F8 formulation
were fixed into various mathematical models and the
results are shown in Table 6.
The drug release pattern of formulation (F7) was
found to be highly linear, and close to infinity as indi-
cated by their high regression value as r2 = 0.993. There-
fore it was ascertained that the drug permeation from
these formulation could follow either near zero or zero
order kinetics.
The in vitro drug release pattern of F8 showed the
highest regression value (r2 = 0.989) for Koresmeyar-
peppas model. The ‘n’ value was found to be between
0.5 and 1 suggesting that release of drug follows anomal-
ous (non-fickian) diffusion mechanism. Release kinetics
may be following both diffusion and erosion mechanism
from these natural gums [32].
In vivo floatability
In vivo floatability studies conducted for F8 showed that
the tablet formulation did not adhere to the gastric mu-
cous and floated in the gastric fluid for more than 24h.
To make the tablet X-ray opaque barium sulphate was
incorporated into the tablet. The amount of barium
sulphate (2mg per tablet) was low enough to enable the
tablet to float, at the same time it was sufficient toHiguchi Koresmeyar- peppas
r2 k r2 n
56 0.948 23.50 0.982 0.954
66 0.981 24.76 0.989 0.819
Figure 6 X-ray photographs showing floating ability of F8
formulation at different time interval (a) 6 h, (b) 12 h and
(c) 24 h.
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photographs taken at 6 h, 12 h & 24 h (Figure 6).
Conclusions
Ziprasidone HCl gastroretentive tablet is developed
using naturally occurring plant based polymers showed
desirable high-drug content, optimal hardness, floatabil-
ity, swelling index and adequate release characteristics.
The systematic formulation approach using simplex lat-
tice design in the study helped in understanding the ef-
fect of formulation variables. The use of plant-based
polymeric can be a good replacement for synthetic poly-
mers in the development of controlled release dosage
forms, because plant based materials can be modified to
meet the requirements of drug delivery systems. Formu-
lations prepared by such renewable and eco-friendly
plant resources can be considered as promising SR poly-
mers substances to bring about sustained release action,
supported by more elaborated research in this aspect.
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